Picture supply: Getty Photos
For an index of typically staid blue-chip shares – a few of which don’t even pay dividends – the FTSE 100 gives some surprisingly profitable revenue shares.
At a time when its common yield is 3.1%, the index’s highest-yielding share gives nicely over twice that a lot, at 8.4%.
It additionally goals to continue to grow its dividend per share yearly, because it has carried out over the previous few years (and, certainly, in most years because the monetary disaster virtually 20 years in the past).
Can it final?
Family identify with an ever-evolving enterprise
The share in query is Authorized & Normal (LSE: LGEN). You recognize, the monetary companies agency with a multi-coloured umbrella as its brand.
Certainly, that broadly identified branding is a part of the corporate’s energy in the case of attracting and retaining prospects.
So too is its heritage. Relationship again to the nineteenth century, the agency’s lengthy historical past can be a supply of consolation for a lot of prospects.
However the firm has not stood nonetheless.
Its enterprise has developed considerably in current many years, with a present strategic deal with retirement-linked merchandise.
That could be a market that advantages from enduring demand and huge market measurement. That may imply it attracts numerous rivals, which is the place I believe Authorized & Normal’s strengths will help set it aside.
Can the dividend continue to grow?
The enterprise itself continues to vary.
The sale of a giant US operation this yr is an instance. Within the short-term that has raised money. Long term, although, it may result in smaller revenues.
In the meantime, does the Metropolis assume Authorized & Normal’s dividend can continue to grow? The annual enhance has already fallen from 5% a couple of years in the past to 2% now.
That’s nonetheless progress, in equity, however weaker progress than earlier than.
The 7% fall within the Authorized & Normal share value over the previous 5 years – a interval that has seen the broader FTSE 100 develop 45% — additionally raises questions concerning the agency’s prospects in my opinion.
Why has the Metropolis marked the share down when the broader index has moved strongly upwards?
A part of the reply might lie in an absence of perceived progress alternatives. Authorized & Normal is a long-established participant in a mature market. Promoting the US operation suggests it might be on a path to shrinking, not rising.
However I believe the larger query many buyers have is whether or not the high-yield share can preserve its dividend. The expansion charge has slowed. Might it cease altogether – and even give approach to a lower in some unspecified time in the future?
Price contemplating for its long-term prospects…
I do contemplate that to be a danger.
I discussed the enterprise sale above. For the remaining rump of the enterprise, rocky monetary markets pose a further danger.
If asset values fall, that might eat into earnings. Nervous markets equal nervous buyers. Which may imply the corporate sees policyholders pulling out extra funds than they make investments.
Nonetheless, Authorized & Normal has confirmed that its enterprise will be extremely money generative.
Final yr demonstrated that once more, with capital era (reported utilizing the Solvency II accounting customary) up 5% to £1.5bn. Given ongoing money era alternatives, I believe the corporate may probably continue to grow its dividend in future.
With a long-term perspective, I see this as a high-yield share for buyers to think about.
Christopher Ruane doesn’t maintain any positions within the firms talked about.
